Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00072618 · ClinicalTrials.gov registry record · Phase 1
Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients
A Phase 1 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT00072618 is a Phase 1 study that has completed, run by Astellas Pharma. The registered enrollment target is 52 participants.
The verdict
NCT00072618, a Phase 1 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the combination of Taxotere and exisulind is an effective and safe treatment for patients with advanced NSCLC who have failed a prior platinum-containing regimen.
Interventions
- DRUG Exisulind
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2001-10 |
| Est. Completion | 2003-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00072618
The ClinicalTrials.gov registry entry for NCT00072618 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Exisulind is the first listed.
NCT00072618 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00072618 about?
NCT00072618 is a clinical study titled "Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients". The purpose of this study is to determine if the combination of Taxotere and exisulind is an effective and safe treatment for patients with advanced NSCLC who have failed a prior platinum-containing regimen.
What is the current status of trial NCT00072618?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2001-10. Estimated completion is 2003-08.
What interventions are being tested in trial NCT00072618?
The interventions under investigation include: Exisulind (DRUG).
Who is sponsoring clinical trial NCT00072618?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.